Suppr超能文献

当推量区距离腮腺较远时,序贯推量计划优于同时推量计划,适用于头颈部癌症患者。

Sequentially delivered boost plans are superior to simultaneously delivered plans in head and neck cancer when the boost volume is located further away from the parotid glands.

机构信息

The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.

出版信息

Radiother Oncol. 2011 Jan;98(1):51-6. doi: 10.1016/j.radonc.2010.10.024. Epub 2010 Dec 8.

Abstract

PURPOSE

To find parameters that predict which head and neck patients benefit from a sequentially delivered boost treatment plan compared to a simultaneously delivered plan, with the aim to spare the salivary glands.

METHODS AND MATERIALS

We evaluated 50 recently treated head and neck cancer patients. Apart from the clinical plan with a sequentially (SEQ) given boost using an Intensity Modulated Radiotherapy Technique (IMRT), a simultaneous integrated boost (SIB) technique plan was constructed with the same beam set-up. The mean dose to the parotid glands was calculated and compared. The elective nodal areas were bilateral in all cases, with a boost on either one side or both sides of the neck.

RESULTS

When the parotid gland volume and the Planning Target Volume (PTV) for the boost overlap there is on average a lower dose to the parotid gland with a SIB technique (-1.2 Gy), which is, however, not significant (p=0.08). For all parotid glands with no boost PTV overlap, there is a benefit from a SEQ technique compared to a SIB technique for the gland evaluated (on average a 2.5 Gy lower dose to the parotid gland, p<0.001). When the distance between gland and PTV is 0-1 cm, this difference is on average 0.8 Gy, for 1-2 cm distance 2.9 Gy and for glands with a distance greater than 2 cm, 3.3 Gy. When the lymph nodes on the evaluated side are also included in the boost PTV, however, this relationship between the distance and the gain of a SEQ seems less clear.

CONCLUSIONS

A sequentially delivered boost technique results in a better treatment plan for most cases, compared to a simultaneous integrated boost IMRT technique, if the boost PTV is more than 1 cm away from at least one parotid gland.

摘要

目的

寻找能够预测头颈部患者从序贯递增强化治疗计划中获益的参数,与同时递增强化计划相比,旨在保护唾液腺。

方法和材料

我们评估了 50 名最近接受治疗的头颈部癌症患者。除了使用强度调制放射治疗技术(IMRT)序贯(SEQ)给予的临床计划外,还构建了具有相同射束设置的同时整合强化(SIB)技术计划。计算并比较了腮腺的平均剂量。所有病例的选择性淋巴结区域均为双侧,颈部的一侧或双侧均有强化。

结果

当腮腺体积和强化的计划靶区(PTV)重叠时,SIB 技术对腮腺的平均剂量较低(-1.2 Gy),但差异无统计学意义(p=0.08)。对于没有强化 PTV 重叠的所有腮腺,与 SIB 技术相比,SEQ 技术对所评估的腮腺有获益(腮腺平均剂量低 2.5 Gy,p<0.001)。当腺体与 PTV 之间的距离为 0-1 cm 时,这种差异平均为 0.8 Gy,距离为 1-2 cm 时为 2.9 Gy,距离大于 2 cm 时为 3.3 Gy。然而,如果评估侧的淋巴结也包含在强化 PTV 中,那么距离与 SEQ 增益之间的关系就不太明显了。

结论

与同时递增强化 IMRT 技术相比,如果强化 PTV 距离至少一个腮腺超过 1 cm,则序贯递增强化技术可使大多数病例获得更好的治疗计划。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验